138 related articles for article (PubMed ID: 28685276)
21. Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma.
Matsui D; Zaidi AH; Martin SA; Omstead AN; Kosovec JE; Huleihel L; Saldin LT; DiCarlo C; Silverman JF; Hoppo T; Finley GG; Badylak SF; Kelly RJ; Jobe BA
Oncotarget; 2016 Dec; 7(49):81281-81291. PubMed ID: 27793030
[TBL] [Abstract][Full Text] [Related]
22. Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma.
Loeser H; Kraemer M; Gebauer F; Bruns C; Schröder W; Zander T; Alakus H; Hoelscher A; Buettner R; Lohneis P; Quaas A
J Immunol Res; 2020; 2020():2862647. PubMed ID: 33029538
[TBL] [Abstract][Full Text] [Related]
23. Role of lymphovascular invasion and immunohistochemical expression of IMP3 in the risk stratification of superficially invasive pT1 esophageal adenocarcinoma.
Trivedi A; Cartun RW; Ligato S
Pathol Res Pract; 2014 Jul; 210(7):402-6. PubMed ID: 24726263
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer.
Tokunaga E; Nakashima Y; Yamashita N; Hisamatsu Y; Okada S; Akiyoshi S; Aishima S; Kitao H; Morita M; Maehara Y
Breast Cancer; 2014 May; 21(3):341-9. PubMed ID: 22903204
[TBL] [Abstract][Full Text] [Related]
25. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience.
Blum Murphy M; Xiao L; Patel VR; Maru DM; Correa AM; G Amlashi F; Liao Z; Komaki R; Lin SH; Skinner HD; Vaporciyan A; Walsh GL; Swisher SG; Sepesi B; Lee JH; Bhutani MS; Weston B; Hofstetter WL; Ajani JA
Cancer; 2017 Nov; 123(21):4106-4113. PubMed ID: 28885712
[TBL] [Abstract][Full Text] [Related]
26. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma.
Sun X; Martin RCG; Zheng Q; Farmer R; Pandit H; Li X; Jacob K; Suo J; Li Y
Cell Oncol (Dordr); 2018 Dec; 41(6):651-662. PubMed ID: 30116994
[TBL] [Abstract][Full Text] [Related]
27. Metadherin regulates actin cytoskeletal remodeling and enhances human gastric cancer metastasis via epithelial-mesenchymal transition.
Du Y; Jiang B; Song S; Pei G; Ni X; Wu J; Wang S; Wang Z; Yu J
Int J Oncol; 2017 Jul; 51(1):63-74. PubMed ID: 28534938
[TBL] [Abstract][Full Text] [Related]
28. [Expression and clinical significance of MTDH and VEGF in triple-negative breast cancer].
Tan L; Qin H; Piao Y; Liu Z; Han Y; Song F; Xie X
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):827-32. PubMed ID: 26887512
[TBL] [Abstract][Full Text] [Related]
29. P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.
van Olphen SH; Biermann K; Shapiro J; Wijnhoven BP; Toxopeus EL; van der Gaast A; Stoop HA; van Lanschot JJ; Spaander MC; Bruno MJ; Looijenga LH
Ann Surg; 2017 Feb; 265(2):347-355. PubMed ID: 28059963
[TBL] [Abstract][Full Text] [Related]
30. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
[TBL] [Abstract][Full Text] [Related]
31. Metadherin is required for the proliferation, migration, and invasion of esophageal squamous cell carcinoma and its meta-analysis.
Yang C; Zheng S; Liu Q; Liu T; Lu M; Dai F; Gao X; Sheyhidin I; Lu X
Transl Res; 2015 Dec; 166(6):614-626.e2. PubMed ID: 26051629
[TBL] [Abstract][Full Text] [Related]
32. Metadherin is a novel prognostic marker for bladder cancer progression and overall patient survival.
Zhou J; Li J; Wang Z; Yin C; Zhang W
Asia Pac J Clin Oncol; 2012 Sep; 8(3):e42-8. PubMed ID: 22898150
[TBL] [Abstract][Full Text] [Related]
33. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological and prognostic significance of epidermal growth factor receptor overexpression in patients with esophageal adenocarcinoma: a meta-analysis.
Guo YM; Yu WW; Zhu M; Guo CY
Dis Esophagus; 2015; 28(8):750-6. PubMed ID: 24961755
[TBL] [Abstract][Full Text] [Related]
35. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation.
Izzo JG; Wu X; Wu TT; Huang P; Lee JS; Liao Z; Lee JH; Bhutani MS; Hofstetter W; Maru D; Hung MC; Ajani JA
Dis Esophagus; 2009; 22(2):127-32. PubMed ID: 19021681
[TBL] [Abstract][Full Text] [Related]
36. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
[TBL] [Abstract][Full Text] [Related]
37. Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma.
Estrella JS; Hofstetter WL; Correa AM; Swisher SG; Ajani JA; Lee JH; Bhutani MS; Abraham SC; Rashid A; Maru DM
Am J Surg Pathol; 2011 Jul; 35(7):1045-53. PubMed ID: 21602659
[TBL] [Abstract][Full Text] [Related]
38. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Resetkova E; Wang H; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Hamilton SR; Albarracin CT
Clin Cancer Res; 2006 Aug; 12(15):4598-604. PubMed ID: 16899607
[TBL] [Abstract][Full Text] [Related]
39. Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival.
Loeser H; Scholz M; Fuchs H; Essakly A; Damanakis AI; Zander T; Büttner R; Schröder W; Bruns C; Quaas A; Gebauer F
Sci Rep; 2020 Oct; 10(1):18411. PubMed ID: 33110104
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of Metadherin-SND1 interaction in colon cancer.
Wang N; Du X; Zang L; Song N; Yang T; Dong R; Wu T; He X; Lu J
Mol Biol Rep; 2012 Dec; 39(12):10497-504. PubMed ID: 23065261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
